Innovent Biologics Inc (6IB) — Cash Flow Reinvestment Rate
Innovent Biologics Inc (6IB) has a Cash Flow Reinvestment Rate of 9.11x as of December 2020, reinvesting €1.99 Billion (capex €211.14 Million plus investments €-1.78 Billion) from operating cash flow of €217.96 Million. Explore Innovent Biologics Inc capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Innovent Biologics Inc Cash Flow Reinvestment Rate (2023–2025)
Historical reinvestment intensity for Innovent Biologics Inc across 3 annual periods. Also explore Innovent Biologics Inc (6IB) total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Innovent Biologics Inc (2023–2025)
Year-by-year capital reinvestment analysis for Innovent Biologics Inc. For live market cap and broader valuation context, see Innovent Biologics Inc stock valuation.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.71x | €7.06 Billion | €10.00 Billion | €683.27 Million | ▼ -48.8% |
| 2024 | 1.38x | €1.78 Billion | €1.29 Billion | €1.71 Billion | ▼ -86.9% |
| 2023 | 10.51x | €1.55 Billion | €147.81 Million | €1.38 Billion | — |